Shares rose 47 percent to $19.58 in early trading after Abbott (NYSE:ABT) agreed to buy Cardiovascular Systems (CSII) for $890 million, or $20 per share, MarketWatch reported. Termao Cardiovascular Systems is a leader in percutaneous atherectomy of transluminal plaques, a minimally invasive treatment for plaque buildup in the arteries. Abbott said the deal’s impact on its recently issued 2023 EPS guidance is neutral.